tbuckley/cabot-search huggingface dataset:
Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
Authors: Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Yesid Alvarado-Valero, Lucia Masarova, Mark Brandt, Debra Bull-Linderman, Naval Daver, Guillermo Montalban-Bravo, Alex Bataller, Guillermo Garcia-Manero, Ghayas C. Issa, Amin Alousi, Nicholas J. Short, Farhad Ravandi, Tapan M. Kadia
Journal: Blood (2023)
Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: A Multicenter Phase II Randomized Clinical Trial
Authors: Leyla Shune, Ayman Qasrawi, Gerhard Hildebrandt, Eric J Huselton, Howard Langstein, Dennis Allin, Kaitlyn Burrows, Andrea M Baran, Jane L. Liesveld, Neil Blumberg, Brea Lipe, Andrew G Evans, Derick R Peterson, Omar Aljitawi
Journal: Blood (2023)
Protective fibroblastic niches in secondary lymphoid organs
Authors: Angelina De Martin, Yves Stanossek, Natalia Barbara Pikor, Burkhard Ludewig
Journal: The Journal of Experimental Medicine (2023)

Fibroblastic reticular cells (FRCs) are specialized fibroblasts of secondary lymphoid organs that provide the structural foundation of the tissue. Moreover, FRCs guide immune cells to dedicated microenvironmental niches where they provide lymphocytes and myeloid cells with homeostatic growth and differentiation factors. Inflammatory processes, including infection with pathogens, induce rapid morphological and functional adaptations that are critical for the priming and regulation of protective immune responses. However, adverse FRC reprogramming can promote immunopathological tissue damage during infection and autoimmune conditions and subvert antitumor immune responses. Here, we review recent findings on molecular pathways that regulate FRC–immune cell crosstalk in specialized niches during the generation of protective immune responses in the course of pathogen encounters. In addition, we discuss how FRCs integrate immune cell–derived signals to ensure protective immunity during infection and how therapies for inflammatory diseases and cancer can be developed through improved understanding of FRC–immune cell interactions.
MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson’s disease
Authors: Lu Geng, Wenqing Gao, Hexige Saiyin, Yuanyuan Li, Yu Zeng, Zhifei Zhang, Xue Li, Zuolong Liu, Qiang Gao, Ping An, Ning Jiang, Xiaofei Yu, Xiangjun Chen, Suhua Li, Lei Chen, Boxun Lu, Aiqun Li, Guoyuan Chen, Yidong Shen, Haibing Zhang, Mei Tian, Zhuohua Zhang, Jixi Li
Journal: Molecular Neurodegeneration (2023)

Parkinson's disease (PD), one of the most devastating neurodegenerative brain disorders, is characterized by the progressive loss of dopaminergic neurons in the substantia nigra (SN) and deposits of α-synuclein aggregates. Currently, pharmacological interventions for PD remain inadequate. The cell necroptosis executor protein MLKL (Mixed-lineage kinase domain-like) is involved in various diseases, including inflammatory bowel disease and neurodegenerative diseases; however, its precise role in PD remains unclear. Here, we investigated the neuroprotective role of MLKL inhibition or ablation against primary neuronal cells and human iPSC-derived midbrain organoids induced by toxic α-Synuclein preformed fibrils (PFFs). Using a mouse model (Tg-Mlkl-/-) generated by crossbreeding the SNCA A53T synuclein transgenic mice with MLKL knockout (KO)mice, we assessed the impact of MLKL deficiency on the progression of Parkinsonian traits. Our findings demonstrate that Tg-Mlkl-/- mice exhibited a significant improvement in motor symptoms and reduced phosphorylated α-synuclein expression compared to the classic A53T transgenic mice. Furthermore, MLKL deficiency alleviated tyrosine hydroxylase (TH)-positive neuron loss and attenuated neuroinflammation by inhibiting the activation of microglia and astrocytes. Single-cell RNA-seq (scRNA-seq) analysis of the SN of Tg-Mlkl-/- mice revealed a unique cell type-specific transcriptome profile, including downregulated prostaglandin D synthase (PTGDS) expression, indicating reduced microglial cells and dampened neuron death. Thus, MLKL represents a critical therapeutic target for reducing neuroinflammation and preventing motor deficits in PD.
Sleep restoration by optogenetic targeting of GABAergic neurons reprograms microglia and ameliorates pathological phenotypes in an Alzheimer’s disease model
Authors: Qiuchen Zhao, Megi Maci, Morgan R. Miller, Heng Zhou, Fang Zhang, Moustafa Algamal, Yee Fun Lee, Steven S. Hou, Stephen J. Perle, Hoang Le, Alyssa N. Russ, Eng H. Lo, Dmitry Gerashchenko, Stephen N. Gomperts, Brian J. Bacskai, Ksenia V. Kastanenka
Journal: Molecular Neurodegeneration (2023)

Abstract Background Alzheimer’s disease (AD) patients exhibit memory disruptions and profound sleep disturbances, including disruption of deep non-rapid eye movement (NREM) sleep. Slow-wave activity (SWA) is a major restorative feature of NREM sleep and is important for memory consolidation. Methods We generated a mouse model where GABAergic interneurons could be targeted in the presence of APPswe/PS1dE9 (APP) amyloidosis, APP-GAD-Cre mice. An electroencephalography (EEG) / electromyography (EMG) telemetry system was used to monitor sleep disruptions in these animals. Optogenetic stimulation of GABAergic interneurons in the anterior cortex targeted with channelrhodopsin-2 (ChR2) allowed us to examine the role GABAergic interneurons play in sleep deficits. We also examined the effect of optogenetic stimulation on amyloid plaques, neuronal calcium as well as sleep-dependent memory consolidation. In addition, microglial morphological features and functions were assessed using confocal microscopy and flow cytometry. Finally, we performed sleep deprivation during optogenetic stimulation to investigate whether sleep restoration was necessary to slow AD progression. Results APP-GAD-Cre mice exhibited impairments in sleep architecture including decreased time spent in NREM sleep, decreased delta power, and increased sleep fragmentation compared to nontransgenic (NTG) NTG-GAD-Cre mice. Optogenetic stimulation of cortical GABAergic interneurons increased SWA and rescued sleep impairments in APP-GAD-Cre animals. Furthermore, it slowed AD progression by reducing amyloid deposition, normalizing neuronal calcium homeostasis, and improving memory function. These changes were accompanied by increased numbers and a morphological transformation of microglia, elevated phagocytic marker expression, and enhanced amyloid β (Aβ) phagocytic activity of microglia. Sleep was necessary for amelioration of pathophysiological phenotypes in APP-GAD-Cre mice. Conclusions In summary, our study shows that optogenetic targeting of GABAergic interneurons rescues sleep, which then ameliorates neuropathological as well as behavioral deficits by increasing clearance of Aβ by microglia in an AD mouse model.
Personalized tumor combination therapy optimization using the single-cell transcriptome
Authors: Chen Tang, Shaliu Fu, Xuan Jin, Wannian Li, Feiyang Xing, Bin Duan, Xiaojie Cheng, Xiaohan Chen, Shuguang Wang, Chenyu Zhu, Gaoyang Li, Guohui Chuai, Yayi He, Ping Wang, Qi Liu
Journal: Genome Medicine (2023)

Abstract Background The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment. Methods Here, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC provides a workable solution to stratify individual patient samples based on quantitative evaluation of their personalized immune microenvironment with single-cell RNA sequencing and maximize the translational potential of in vitro cellular response to unify the identification of synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors to boost immunotherapy from a large collection of small molecules and drugs, and finally prioritize them for personalized clinical use based on bipartition graph optimization. Results We apply comboSC to publicly available 119 single-cell transcriptome data from a comprehensive set of 119 tumor samples from 15 cancer types and validate the predicted drug combination with literature evidence, mining clinical trial data, perturbation of patient-derived cell line data, and finally in-vivo samples. Conclusions Overall, comboSC provides a feasible and one-stop computational prototype and a proof-of-concept study to predict potential drug combinations for further experimental validation and clinical usage using the single-cell transcriptome, which will facilitate and accelerate personalized tumor treatment by reducing screening time from a large drug combination space and saving valuable treatment time for individual patients. A user-friendly web server of comboSC for both clinical and research users is available at www.combosc.top . The source code is also available on GitHub at https://github.com/bm2-lab/comboSC .
TargetRNA3: predicting prokaryotic RNA regulatory targets with machine learning
Authors: Brian Tjaden
Journal: Genome biology (2023)

Abstract Small regulatory RNAs pervade prokaryotes, with the best-studied family of these non-coding genes corresponding to trans -acting regulators that bind via base pairing to their message targets. Given the increasing frequency with which these genes are being identified, it is important that methods for illuminating their regulatory targets keep pace. Using a machine learning approach, we investigate thousands of interactions between small RNAs and their targets, and we interrogate more than a hundred features indicative of these interactions. We present a new method, TargetRNA3, for predicting targets of small RNA regulators and show that it outperforms existing approaches. TargetRNA3 is available at https://cs.wellesley.edu/~btjaden/TargetRNA3 .
HIV diagnoses among people born in Ukraine reported by EU/EEA countries in 2022: impact on regional HIV trends and implications for healthcare planning
Authors: Juliana Reyes-Urueña, Gaetano Marrone, Teymur Noori, Giorgi Kuchukhidze, Violetta Martsynovska, Larysa Hetman, Anton Basenko, Stela Bivol, Marieke J van der Werf, Anastasia Pharris
Journal: Eurosurveillance (2023)

Following Russia’s invasion in 2022, over 4.1 million Ukrainians sought refuge in the EU/EEA. We assessed how this impacted HIV case reporting by EU/EEA countries. Ukrainian refugees constituted 10.2% (n = 2,338) of all 2022 HIV diagnoses, a 10-fold increase from 2021. Of these, 9.3% (n = 217) were new diagnoses, 58.5% (n = 1,368) were previously identified; 32.2% had unknown status. Displacement of Ukrainians has partly contributed to increasing HIV diagnoses in EU/EEA countries in 2022, highlighting the importance of prevention, testing and care.
Ecological and clinical evidence of the establishment of West Nile virus in a large urban area in Europe, Berlin, Germany, 2021 to 2022
Authors: Claudia Ruscher, Corinna Patzina-Mehling, Julia Melchert, Selina L Graff, Sarah E McFarland, Christian Hieke, Anne Kopp, Anita Prasser, Torsten Tonn, Michael Schmidt, Caroline Isner, Christian Drosten, Dirk Werber, Victor M Corman, Sandra Junglen
Journal: Eurosurveillance (2023)

Background West Nile virus (WNV), found in Berlin in birds since 2018 and humans since 2019, is a mosquito-borne virus that can manifest in humans as West Nile fever (WNF) or neuroinvasive disease (WNND). However, human WNV infections and associated disease are likely underdiagnosed. Aim We aimed to identify and genetically characterise WNV infections in humans and mosquitoes in Berlin. Methods We investigated acute WNV infection cases reported to the State Office for Health and Social Affairs Berlin in 2021 and analysed cerebrospinal fluid (CSF) samples from patients with encephalitis of unknown aetiology (n = 489) for the presence of WNV. Mosquitoes were trapped at identified potential exposure sites of cases and examined for WNV infection. Results West Nile virus was isolated and sequenced from a blood donor with WNF, a symptomatic patient with WNND and a WNND case retrospectively identified from testing CSF. All cases occurred in 2021 and had no history of travel 14 days prior to symptom onset (incubation period of the disease). We detected WNV in Culex pipiens mosquitoes sampled at the exposure site of one case in 2021, and in 2022. Genome analyses revealed a monophyletic Berlin-specific virus clade in which two enzootic mosquito-associated variants can be delineated based on tree topology and presence of single nucleotide variants. Both variants have highly identical counterparts in human cases indicating local acquisition of infection. Conclusion Our study provides evidence that autochthonous WNV lineage 2 infections occurred in Berlin and the virus has established an endemic maintenance cycle.
The molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine
Authors: Anna Weibull Wärnberg, Johanna Brännström, Olof Elvstam, Magnus Gisslén, Fredrik Månsson, Anders Sönnerborg, Maarten AA van de Klundert
Journal: Eurosurveillance (2023)

Background The global distribution of HIV-1 subtypes is evolving, which is reflected in the Swedish HIV cohort. The subtype HIV-1A6, which may be prone to developing resistance to cabotegravir, is the most common subtype in Ukraine. Aim We aimed to examine trends in HIV-1 subtype distribution in Sweden, with a special focus on HIV-1A6, and to describe the virology, demography and treatment of Ukrainian people living with HIV (PLWH) who migrated to Sweden in 2022. Methods Data about PLWH in Sweden are included in a national database (InfCareHIV). We used the online tool COMET to establish HIV-1 subtypes and the Stanford database to define drug resistance mutations. We investigated the relation between virological characteristics and demographic data. Results The early epidemic was predominated by HIV-1 subtype B infections in people born in Sweden. After 1990, the majority of new PLWH in Sweden were PLWH migrating to Sweden, resulting in an increasingly diverse epidemic. In 2022, HIV-1A6 had become the sixth most common subtype in Sweden and 98 of the 431 new PLWH that were registered in Sweden came from Ukraine. We detected HIV RNA in plasma of 32 Ukrainian patients (34%), of whom 17 were previously undiagnosed, 10 had interrupted therapy and five were previously diagnosed but not treated. We found HIV-1A6 in 23 of 24 sequenced patients. Conclusion The molecular HIV epidemiology in Sweden continues to diversify and PLWH unaware of their HIV status and predominance of HIV-1A6 should be considered when arranging care directed at PLWH from Ukraine.
Necessary Role of Ceramides in the Human Microvascular Endothelium During Health and Disease
Authors: Gopika SenthilKumar, Boran Katunaric, Zachary Zirgibel, Brian Lindemer, Maria J. Jaramillo-Torres, Henry Bordas-Murphy, Mary E. Schulz, Paul J. Pearson, Julie K. Freed
Journal: Circulation Research (2023)

Elevated plasma ceramides and microvascular dysfunction both independently predict adverse cardiac events. Despite the known detrimental effects of ceramide on the microvasculature, evidence suggests that activation of the shear-sensitive, ceramide-forming enzyme NSmase (neutral sphingomyelinase) elicits formation of vasoprotective nitric oxide (NO). Here, we explore a novel hypothesis that acute ceramide formation through NSmase is necessary for maintaining NO signaling within the human microvascular endothelium. We further define the mechanism through which ceramide exerts beneficial effects and discern key mechanistic differences between arterioles from otherwise healthy adults (non-coronary artery disease [CAD]) and patients diagnosed with CAD.
<i>Forsythia velutina</i> Nakai extract: A promising therapeutic option for atopic dermatitis through multiple cell type modulation
Authors: Yujin Kwon, Yoon Jin Kang, Jaeyoung Kwon, Su‐Yeon Cho, Jiyoon Kim, Tam Thi Le, Hoseong Hwang, Barsha Deshar, Myungjun Kim, Ju Yeong Kim, Jae Hung Jung, Hyung‐Sik Kim, Sang Hoon Jung, Hak Cheol Kwon, Won Kyu Kim
Journal: Allergy (2023)

Abstract Background Atopic dermatitis (AD) is a complex condition characterized by impaired epithelial barriers and dysregulated immune cells. In this study, we demonstrated Forsythia velutina Nakai extract (FVE) simultaneously inhibits basophils, macrophages, keratinocytes, and T cells that are closely interrelated in AD development. Methods We analyzed the effect of FVE on nitric oxide and reactive oxygen species (ROS) production in macrophages, basophil degranulation, T cell activation, and tight junctions in damaged keratinocytes. Expression of cell‐type‐specific inflammatory mediators was analyzed, and the underlying signaling pathways for anti‐inflammatory effects of FVE were investigated. The anti‐inflammatory effects of FVE were validated using a DNCB‐induced mouse model of AD. Anti‐inflammatory activity of compounds isolated from FVE was validated in each immune cell type. Results FVE downregulated the expression of inflammatory mediators and ROS production in macrophages through TLR4 and NRF2 pathways modulation. It significantly reduced basophil degranulation and expression of type 2 (T2) and pro‐inflammatory cytokines by perturbing FcεRI signaling. Forsythia velutina Nakai extract also robustly inhibited the expression of T2 cytokines in activated T cells. Furthermore, FVE upregulated the expression of tight junction molecules in damaged keratinocytes and downregulated leukocyte attractants, as well as IL‐33, an inducer of T2 inflammation. In the AD mouse model, FVE showed superior improvement in inflammatory cell infiltration and skin structure integrity compared to dexamethasone. Dimatairesinol, a lignan dimer, was identified as the most potent anti‐inflammatory FVE compound. Conclusion Forsythia velutina Nakai extract and its constituent compounds demonstrate promising efficacy as a therapeutic option for prolonged AD treatment by independently inhibiting various cell types associated with AD and disrupting the deleterious link between them.
Practice Patterns of Transplant Centers Regarding Maintenance Treatment Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Survey on Behalf of the EBMT Acute Leukemia Working Party
Authors: Iman Abou Dalle, Myriam Labopin, Irma Khvedelidze, Frederic Baron, Eolia Brissot, Gesine Bug, Jordi Esteve, Sebastian Giebel, Norbert Claude Gorin, Francesco Lanza, Arnon Nagler, Zina Peric, Simona Piemontese, Annalisa Ruggeri, Jaime Sanz, Bipin N. Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty
Journal: Blood (2023)
Allogeneic Hematopoietic Cell Transplantation for Acute Megakaryocytic Leukemia: A Single Center Study
Authors: Shruthi Suryaprakash, Yu Bi, Subodh Selukar, Dinesh Keerthi, Amr Qudeimat, Aimee C. Talleur, Ewelina K. Mamcarz, Ashok Srinivasan, Madden Renee, Rebecca Epperly, Swati Naik, Stephen Gottschalk, Brandon M Triplett, Akshay Sharma
Journal: Blood (2023)
Central Retinal Vein Occlusion (CRVO) in Acute Lymphoblastic Leukaemia (ALL) Adult Patient Treated with Peg Asparaginase
Authors: Jassim Ahmed Khan, Nancy Kessam, Samah Ahmed Samy Kohla, Awni Alshurafa, Usman Naeem, Halima El Omri, Shehab Mohamed, Amna Gameil
Journal: Blood (2023)
Direct, Potent, and TP53-Independent Activity of Sting Agonists Against Acute Myeloid Leukaemia Enhances Venetoclax Efficacy <i>In Vivo</i>
Authors: Yin Yuan, Sarah T Diepstraten, Fiona C. Brown, Veronique Litalien, Andreas Strasser, Gemma L Kelly, Andrew W. Roberts, Andrew H. Wei
Journal: Blood (2023)
Preclinical Evaluation of Bisantrene As Single Agent and in Combination with Decitabine for Acute Myeloid Leukemia
Authors: Nicole M Verrills, Heather C Murray, Joshua S Brzozowski, Nikita Panicker, Kasey Miller, Marinella Messina, Benjamin J Buckley, Michael J Kelso, Anoop K Enjeti
Journal: Blood (2023)
Real-Life Data of Bosutinib Treatment for Chronic Myeloid Leukemia: The Multi-Center Experience of the <i>Gruppo Di Miglioramento Sicilia-Calabria</i>
Authors: Marco Santoro, Sabina Russo, Iolanda Donatella Vincelli, Emilia Cotzia, Stefana Impera, Vincenzo Leone, Luciano Levato, Francesco Mendicino, Alessandra Malato, Mineo Giuseppe, Laura Nocilli, Ferdinando Porretto, Bruno Martino, Sergio Siragusa, Carmela Anna Maria Tomaselli
Journal: Blood (2023)
Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data
Authors: Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu
Journal: Blood (2023)
CD19-CAR Cytokine Induced Killer Cells Armored with IL-18 Control Tumor Burden, Prolong Mouse Survival and Result in <i>In Vivo</i> Persistence of CAR-CIK Cells in a Model of B-Cell Acute Lymphoblastic Leukemia
Authors: Mark Debenedette, Terence J Purdon, James Ryan McCloud, Ana Plachco, Marcus Norris, Alicia Gamble, John F Krisko, Irina Y Tcherepanova, Charles A Nicolette, Renier Brentjens
Journal: Blood (2023)
Real World Outcomes of Patients with Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation after Induction with Liposomal Daunorubicin-Cytarabine (CPX-351)
Authors: Guneet Kaleka, Dat Ngo, Dongyun Yang, Sally Mokhtari, Guido Marcucci, Ryotaro Nakamura, Vinod Pullarkat, Caspian H. Oliai, Amandeep Salhotra
Journal: Blood (2023)
Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms
Authors: Eli L. Diamond, Benjamin Durham, Ahmet Dogan, Mariko Yabe, Kseniya Petrova-Drus, Raajit K. Rampal, Raajit K. Rampal, Gary Ulaner, Mario Lacouture, Veronica Rotemberg, Anne Covey, Lynn Brody, Omar Abdel-Wahab
Journal: Blood (2023)
Efficacy and Safety of FLT-3 Inhibitors in Newly Diagnosed FLT-3 Mutated AML Patients: A Systematic Review of Clinical Trials
Authors: Muhammad Ashar Ali, Bader Al Omour, Wajeeha Aiman, Nibras Yar khan, Sahar Memar Montazerin, Himaja Dutt Chigurupati, Ayushi Mohan, Muhammad Yasir Anwar, Gunwant Guron, Michael Maroules, Hamid Shaaban
Journal: Blood (2023)
Clinical and Prognostic Validation of the Reticulin, Collagen, Osteosclerosis (RCO) Score for Primary Myelofibrosis (PMF)
Authors: Giacomo Coltro, Raffaella Santi, Giuseppe Gaetano Loscocco, Alessandro Atanasio, Paolo Cicogna, Paola Guglielmelli, Umberto Gianelli, Alessandro M. Vannucchi
Journal: Blood (2023)
Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States (US): A Qualitative Study
Authors: Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Yi-Hsuan Liu, Kevin C De Braganca, Nicole Lodowski, Jennifer Sander Kirschenbaum, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Krina K. Patel
Journal: Blood (2023)
Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML
Authors: Xiaohui Suo, Guanchen Bai, Xingli Zhao, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Xinxiao Lu, Linyu Yuan, Yingchang Mi, Kaiqi Liu
Journal: Blood (2023)
High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia
Authors: Josette M Kamel, Mendel Goldfinger, Jiani Chai, Jui Choudhuri, Marina Y. Konopleva, Eric J Feldman, Ioannis Mantzaris, Dennis L Cooper, Aditi Shastri, Nishi Shah, Noah Kornblum, Kira Gritsman, Alejandro Sica, Yanhua Wang, Xuejun Tian, Amit Verma, Swati Goel
Journal: Blood (2023)